लोड हो रहा है...

A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients

RATIONALE: The hypomethylating agent 5-azacytidine has been approved in Europe for patients with intermediate 2 and high (i.e., higher) risk myelodysplastic syndrome according to the International Prognostic Scoring System (IPSS). A total of 91% of all first responses in higher risk patients occur w...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Medicine (Baltimore)
मुख्य लेखकों: Spetsieris, Nikolaos, Diamantopoulos, Panagiotis, Zervakis, Konstantinos, Giannakopoulou, Nefeli, Rougala, Niki, Garefalakis, Georgios, Skarlatou, Vasiliki, Viniou, Nora-Athina
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Wolters Kluwer Health 2018
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5944567/
https://ncbi.nlm.nih.gov/pubmed/29703015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000010505
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!